ACXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acurx Pharmaceuticals Inc (ACXP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's advancements in its antibiotic pipeline, particularly ibezapolstat, and positive regulatory guidance from the EMA provide strong long-term growth potential. The technical indicators, while showing short-term bearish trends, indicate an oversold condition (RSI at 19.886), suggesting a potential rebound. Despite the lack of significant trading trends or Congress trading data, the positive news catalysts and promising stock trend probabilities make it a suitable investment for long-term growth.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 19.886, signaling an oversold condition and potential for a rebound. However, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a short-term downtrend. Key support is at 1.524, and resistance is at 1.626.
Advancement of ibezapolstat to Phase 3 clinical trials for Clostridioides difficile infections. Positive regulatory guidance from the EMA supports the Phase 3 program and potential European market entry. Promising pipeline targeting antibiotic-resistant Gram+ bacteria.
Bearish moving averages and lack of significant insider or hedge fund trading trends. No recent Congress trading data.
No financial data available for analysis.
No analyst rating or price target changes provided.
